Stroke treatment shows promise

Israel’s D-Pharm has announced successful interim results in the Phase IIa clinical trial of its drug THR-18 taken in conjunction with tissue plasminogen activator (tPA) for the treatment of cerebral stroke. D-Pharm’s share price rose 117%, despite the trials taking place in the Ukraine.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *